Bevacizumab, an anti-VEGF antibody, is effective in treating bleeding and anemia in HHT [26,27,28,29], while nasal bevacizumab did not have a significant impact on controlling nasal bleeding [30]. The gene discussed is VEGFA; the disease is anemia (phenotype).